Patents by Inventor Shahnaz H. Dairkee

Shahnaz H. Dairkee has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • Composition containing CEA/NCA-specific monoclonal antibody XMMBR-B14 conjugated to a detectable moiety and a kit containing the antibody
    Patent number: 5225541
    Abstract: The present invention provides a composition consisting of a monoclonal antibody that defines an epitope found on an antigen antigen/normal cross-reacting antigen produced by hybridoma XMMBR-B14 (HB 9308) conjugated to a detectable moiety, and a kit containing the antibody. Hybridoma XMMBR-B14 was deposited with the ATCC on Jan. 14, 1987 and given the ATCC Accession No. HB 9308.
    Type: Grant
    Filed: August 1, 1989
    Date of Patent: July 6, 1993
    Assignee: Peralta Cancer Research Institute
    Inventors: Adeline J. Hackett, Shahnaz H. Dairkee
  • Methods and compositions for screening carcinomas
    Patent number: 5158893
    Abstract: Methods for determining the prognosis of human carcinomas utilizing a marker specific for malignant cells of aggressive cancers. Cell lines have been produced that secrete monoclonal antibodies useful in detecting such markers, including a 51,000-dalton keratin protein, specific for myoepithelial cells, e.g., in tissue culture. Pharmaceutical compositions containing these antibodies, which can be in combination with cytotoxic agents and the use of such compositions in the management of carcinomas are included.Prior to filing of this patent application, the continuous transformed cell lines described herein was deposited in the American Type Culture Collection and designated Accession No. HB9288.
    Type: Grant
    Filed: April 17, 1990
    Date of Patent: October 27, 1992
    Assignee: Peralta Cancer Research Institute
    Inventors: Adeline J. Hackett, Shahnaz H. Dairkee
  • Hybridoma cell line XMMBR-B14 and monoclonal antibody which is specific for a non-cross reactive epitope of CEA
    Patent number: 4853464
    Abstract: The present invention provides a novel hybridoma cell line secreting monoclonal antibodies (MoAbs) that define an epitope found on an antigen of the classification termed CEA/NCA (carcinoembryonic antigen/normal cross-reacting antigen). The MoAbs of the invention find particular utility as the targeting moiety of immunotoxin and immunoimaging conjugates.Hybridoma XMMBR-B14 was deposited with the A.T.C.C. on Jan. 14, 1987 and given A.T.C.C. Accession No. HB 9308.
    Type: Grant
    Filed: February 16, 1988
    Date of Patent: August 1, 1989
    Assignee: Peralta Cancer Research Institute
    Inventors: Adeline J. Hackett, Shahnaz H. Dairkee